The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...

Denosumab-bnht is expected to launch in the US in June 2025 per an agreement with the reference product’s manufacturer, Amgen ...

Shanghai, China & JERSEY CITY, N.J., United States: ...

Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) of its operating company Fresenius Kabi, has ...

In an expert call, the brokerage addressed possibilities of pass-through of tariffs to consumers, and the feasibility of ...

Indian pharma companies may stand to gain market share due to the potential impact of US tariffs, according to a JPMorgan ...

Indian pharma companies may stand to gain market share due to the potential impact of US tariffs, according to a JPMorgan rep ...

Commentary: New York must take on Big Pharma by demanding more transparency in pricing and ensuring generics aren't delayed ...

Did you know that every third tablet consumed globally is manufactured in India? Yes, you heard that right. India’s pharma ...

Innovent is a leading biotech company in China with strong roots in oncology, anchored by its core PD-1 drug Tyvyt. The price cut for PD-1 drugs has stabilized gradually. Hence, we expect stable ...

ABB India, PB Fintech, Info Edge, and Dr. Agarwal's Eye Hospital are some of the other stocks on analysts' radar.